List of Figures

#	Title	Page
Fig. 1.1	Share of obese adults in 2016 (A) and share of obese associated deaths in 2017 (B)	2
Fig. 1.2	Structure of the proposed ABCD systems	4
Fig. 1.3	Structures of approved drugs for the treatment of obesity	6
Fig. 1.4	The physiological role of PL in lipid digestion.	8
Fig. 1.5	Representation of open and closed lid forms of human PL	10
Fig. 1.6	Mode of action of Orlistat	11
Fig. 1.7	Structure of Cetilistat	12
Fig. 2.1	USFDA approved natural product/inspired drugs in 2019 (with their clinical condition)	17
Fig. 2.2	General classification of polyphenol-based PL inhibitors	19
Fig. 2.3	Chemical structures of polyphenols isolated from tea	21
Fig. 2.4	Chemical structures of polyphenols isolated from various plants	24
Fig. 2.5	Chemical structures of polyphenols containing prenyl/geranyl substitutions	25
Fig. 2.6	Chemical structures of stilbene type polyphenols having PL inhibition potential	26
Fig. 2.7	Chemical structures of benzofuran type polyphenols with PL inhibition activity	27
Fig. 2.8	Chemical structures of various saponins with PL inhibitory activity	29
Fig. 2.9	Chemical structures of various alkaloids with PL inhibitory activity	30
Fig. 2.10	Chemical structures of various terpenoids with PL inhibitory activity	31
Fig. 2.11	Chemical structures of various β-lactone containing microbial metabolites with PL inhibitory activity	32
Fig. 2.12	Various monascus pigments and their PL inhibitory activity	33
Fig. 2.13	Boronic acids and phosphonates based PL inhibitors	35
Fig. 2.14	5-Methoxy-*N*-3-phenyl substituted-1,3,4-oxadiazol-2(3H)-	35

	ones and 5-Alkoxy-*N*-3-(3-phenoxyphenyl)-1,3,4-oxadiazol-2(3H)-one based PL inhibitors	
Fig. 2.15	Benzyltetrahydroisoquinoline scaffold-based PL inhibitors	36
Fig. 2.16	Benzimidazole, benzimidazole with perimidine, bisbenzimidazole, quinazoline-coumarin and triazole-coumarin hybrid analogues based PL inhibitors	37
Fig. 2.17	Carbazolyl/indolyl oxoacetamide based PL inhibitors	37
Fig. 2.18	Thiazolidinedione and rhodanine based PL inhibitors	38
Fig. 3.1	Superimposition of the re-docked pose of MUP (Grey) with the co-crystallised pose (Green).	51
Fig. 4.1	Representative image of *A. scholaris* leaves and stem barks	56
Fig. 4.2	Representative examples of various phytochemicals isolated from *A. scholaris*	57
Fig. 4.3	Schematic representation of bioassay guided fractionation of methanol extract prepared from continuous hot percolation technique	58
Fig. 4.4	Structure of Echitamine	59
Fig. 4.5	A) Spectral scan chromatogram of echitamine highlighting the λ_{max} at 294 nm; B) HRMS spectrum of echitamine	62
Fig. 4.6	A) TLC of echitamine (Track 2) and different extracts (Track 1,3 and 4) prepared from different extraction techniques, derivatized used anisaldehyde-sulphuric acid; B) HPTLC chromatograms of echitamine, different extracts and scanned densitometrically at 530 nm.	63
Fig. 4.7	Regression plot representing the linearity of the validated HPTLC method.	64
Fig. 4.8	Representation of PL inhibitory activity (IC_{50}) (A) and extractive yield of echitamine (B) from extracts prepared via different extraction techniques in the stem bark of *A. scholaris* on dry weight basis	67
Fig. 5.1	2-D interaction diagram of Orlistat and Echitamine with the active site of PL (1LPB)	71
Fig. 5.2	Structures of some indole and TZD containing analogues	72

	reported for metabolic disease (insight represent the pharmacophoric design of the target analogues).	
Fig. 5.3	Rationale for the designing of the hybrid analogues	73
Fig. 5.4	Double reciprocal Lineweaver-Burk plots of analogues **5r**, **5t** and orlistat	88
Fig. 5.5	Structure–activity relationship of synthesized Indole-TZD hybrid analogues (**5a**-**5ag**)	89
Fig. 5.6	(A), (B) The fluorescence spectra of PL in the presence of **5r** and **5t** at various concentrations (pH 7.4, T = 298 K); (C), (D) Stern−Volmer plots for the quenching of **5r** and **5t** on the PL at 300 K	90
Fig. 5.7	Binding pose and 2D interaction diagram of **5r** (A) and **5t** (B) in the active site of PL (1LPB)	95
Fig. 5.8	RMSD of Ligands and Radius of gyrations retrieved from 20 ns MD simulations of the PL-ligand complex (A)- **5r**; (B)-**5t**.	96
Fig. 6.1	(A) 3D poses of orlistat and **5r** highlighting the distance of reactive carbonyl from Ser152 (3.02 and 3.25 Å, respectively); (B) 2D interactions of orlistat and 5r	104
Fig. 6.2	Rationale for designing series II Indole-TZD analogues as PL inhibitors. The interaction distance has reduced from 3.25 Å in **5r** (A) to 3.16 Å by the incorporation of an additional carbon linker (B)	105
Fig. 6.3	Double reciprocal Lineweaver-Burk plots of analogues **6d** and **6e**	118
Fig. 6.4	Structure-activity relationship of synthesized Indole-TZD hybrid analogues (**6a**-**6ab**)	119
Fig. 6.5	(A), (B) The fluorescence spectra of PL in the presence of **6d** and **6e** at various concentrations (pH 7.4); (C), (D) Stern−Volmer plots for the quenching of **6d** and **6e** on the PL at 300K	120
Fig. 6.6	Binding pose and 2D interaction diagram of **6d** (A) and **6e** (B) in the active site of PL (1LPB)	125
Fig. 6.7	RMSD of Ligands and Radius of gyrations retrieved from 20 ns MD simulations of the PL-ligand complex (A)- **6d**; (B)- **6e**.	126

Fig. 7.1	Overlay diagram indicating the importance of linker extension and indole scaffold. **6d** (Brown); A- Extension of linker by phenyl and phenethyl functionality; B- Extension of linker by phenethyl and ethyl indole functionality	131
Fig. 7.2	Structures of prenyl/geranyl containing natural products.	132
Fig. 7.3	Rationale for the designing of the hybrid analogues	132
Fig. 7.4	Double reciprocal Lineweaver-Burk plots of analogues **7m** and **7r**	144
Fig. 7.5	Structure–activity relationship of synthesized Indole-TZD hybrid analogues (**7a**-**7u**)	145
Fig. 7.6	(A), (B) The fluorescence spectra of PL in the presence of **7m** and **7r** at various concentrations (pH 7.4); (C), (D) Stern−Volmer plots for the quenching of 7m and 7r on the PL	146
Fig. 7.7	Binding pose and 2D interaction diagram of **7m** (A) and **7r** (B) in the active site of PL (1LPB)	148
Fig. 7.8	2D docking poses of **7m** (A), **7r** (B), **7s** (C), **7t** (D), **7u** (F) highlighting the distance of the reactive carbonyl from Ser 152; F- 6 methoxy substituted analogue.	149
Fig. 7.9	RMSD of ligands and radius of gyrations retrieved from 20 ns MD simulations of the PL-ligand complexes (A)-**7m** and (B)-**7r**	152
Fig. 8.1	Results of the OTTT summarizing the serum triglyceride levels at various time points.	163
Fig. 8.2	Increment in body weights of various groups during the treatment period.	164
Fig. 8.3	Various biochemical parameters determined after the treatment period.	165
Fig. 8.4	Faecal triglyceride levels determined from various groups.	166

List of Tables

#	Title	Page
Table 1.1	Summary of BMI based classification for overweight and obesity in different age groups.	3
Table 1.2	Currently approved anti-obesity medications	5
Table 1.3	Current status of various antiobesity investigational new drugs	7
Table 2.1	Polyphenols reported from tea with PL inhibitory activity	20
Table 2.2	Polyphenols reported from various plants with PL inhibitory activity	23
Table 2.3	Prenyl/ geranyl substituted polyphenols with PL inhibitory activity	25
Table 2.4	Stilbene based PL inhibitors	26
Table 2.5	Saponin based PL inhibitors	28
Table 2.6	Alkaloid based PL inhibitors	30
Table 2.7	Terpenoid based PL inhibitors	31
Table 4.1	PL inhibitory activity of 90 extracts obtained from 15 plants	55
Table 4.2	Taxonomical classification of *A. scholaris*	56
Table 4.3	Summary of the validated HPTLC parameters for echitamine.	63
Table 4.4	Summary of intra- and inter-day accuracy and precision studies	64
Table 4.5	Recovery study of the developed method summarizing the % recovery values	65
Table 4.6	Summary of robustness results of the developed method.	66
Table 5.1	*In-vitro* PL inhibitory activity of the synthesized analogues (**5a- 5ag**)	87
Table 5.2	K_m, V_{max} and K_i values of **5r** and **5t** retrieved from the PL enzyme kinetics.	88
Table 5.3	Bimolecular quenching constant (K_q), binding constant (K_b) and the number of binding sites (n) at different temperatures for **5r** and **5t**	92
Table 5.4	Mol Dock scores (in kcal/ mol) and the interaction summary of the synthesized analogues (**5a- 5ag**) with the human PL active site of 1LPB	93

Table 5.5	Various interactions exhibited by **5r** and **5t** during the 20 ns MD run	97
Table 6.1	*In-vitro* PL inhibitory activity of the synthesized analogues (**6a- 6ab**)	117
Table 6.2	K_m, V_{max} and K_i values of **6d** and **6e** retrieved from the PL enzyme kinetics	118
Table 6.3	Bimolecular quenching constant (K_q), binding constant (K_b) and the number of binding sites (n) at different temperatures for **6d** and **6e**	121
Table 6.4	Mol Dock scores (in kcal/ mol) and the interaction summary of the synthesized analogues (**6a- 6ab**) with the human PL active site of 1LPB	122
Table 6.5	Various interactions exhibited by **6d** and **6e** during the 20 ns MD run	127
Table 7.1	*In-vitro* PL inhibitory activity of the synthesized analogues (**7a- 7u**)	143
Table 7.2	K_m, V_{max} and K_i values of **7r** and **7m** retrieved from the PL enzyme kinetics	144
Table 7.3	Bimolecular quenching constant (K_q), binding constant (K_b) and the number of binding sites (n) at different temperatures for **7m** and **7r**	147
Table 7.4	Mol Dock scores (in kcal/ mol) and the interaction summary of the synthesized analogues (**7a- 7u**) with the human PL active site of 1LPB	150
Table 7.5	Various interactions exhibited by **7m** and **7r** with PL during the 20 ns MD run	153
Table 8.1	Summary of various groups and drugs administered for the *in-vivo* experiments	160
Table 8.2	Composition of the HFD used in the *in-vivo* experiments.	160
Table 8.3	Summary of ADMET parameters predicted for the potential analogues from each series along with echitamine and orlistat	162

List of Schemes and Formulae

#	Title	Page
Scheme 5.1	Synthesis of the series I analogues (**5a - 5ag**).	74
Scheme 6.1	Synthesis of series II analogues (**6a - 6ab**).	105
Scheme 7.1	Synthesis of series III analogues (**7a- 7u**).	133
Formula 1.1	Body Mass Index	3
Formula 3.1	PL inhibition	50
Formula 5.1	Stern−Volmer equation	91
Formula 5.2	Modified Stern−Volmer equation	92
Formula 8.1	Low-density lipoprotein-cholesterol	161

List of Abbreviations and Symbols

%	Percentage
% CV	Percent coefficient of variation
% RSD	Percent relative standard deviation
% v/v	Percent volume by volume
% w/v	Percent weight by volume
Å	Angstrom
°C	Degree celsius
δ	Delta
µg	Microgram
µL	Microliter
µM	Micromolar
4-NPB	4-nitrophenyl butyrate
5-HT_{2C}	5-Hydroxytryptamine type 2C receptor
ADMET	Absorption, Distribution, Metabolism, Excretion and Toxicity
ARF	Alkaloid rich fractions
BBB	Blood Brain Barrier
BMI	Body Mass Index
CB_1	Cannabinoid type 1 receptor
CHARMM	Chemistry at Harvard Macromolecular Mechanics
CM	Cold Maceration
CNS	Central Nervous System
Conc.	Concentration
CYP	Cytochrome P
Da	Dalton
DCM	Dichloromethane
DMF	Dimethyl formamide
DMSO	Dimethyl sulfoxide
e.g.	Example
ESI	Electrospray ionization
eV	Electron volt
FDA	Food and drug administration
FTIR	Fourier Transform Infrared

G	gram
GABA	Gamma aminobutyric acid
GI	Gastro-Intestinal
GLP-1	Glucagon like peptide type 1 receptor
GROMACS	GROningen Machine for Chemical Simulations
H	Hour
HCl	Hydrochloric acid
HDL	High-density lipoproteins
HFD	High Fat Diet
HP	Hot Percolation
HPLC	High Performance Liquid Chromatography
HPTLC	High Performance Thin Layer Chromatography
HQC	High quality control
HRMS	High Resolution Mass Spectrometry
i.e	That is
IC_{50}	Half maximal inhibitory concentration
ICH	International Conference on Harmonization
IEAC	Institutional animal ethics committe
Kcal/mol	Kilocalorie per mole
Kg	kilogram
KOH	Potassium hydroxide
LCMS	Liquid Chromatography Mass Spectrometry
LD_{50}	Half maximal Lethal Dose
LDL	Low-density lipoproteins
LINCS	Linear Constraint Solver
LOD	Limit of Detection
LOQ	Limit of Quantification
m.p.	Melting point
MD	Molecular Dynamics
mg	Milligram
min	Minutes
mL	Millilitre
mM	Millimolar

MM2	Molecular Mechanics 2
MQC	Mid quality control
MUP	Methoxyundecyl phosphinic acid
ng	Nanogram
NMR	Nuclear Magnetic Resonance
NP	Natural Product
NPD	Normal Pellet Diet
NPT	No. of particles, Pressure and Temperature
ns	not significant
NVT	No. of particles, Volume and Temperature
OTTT	Oral Triglyceride Tolerance Test
PDB	Protein Data Bank
Pgp	P-glycoprotein
PL	Pancreatic lipase
RMSD	Root Mean Square Deviation
rpm	Rotations per minute
RSD	Relative Standard Deviation
RT	Room Temperature
S.E.M	Standard error of mean
SD	Standard Deviation
STEPS	STEPwise Approach to Surveillance
TC	Total cholesterol
TCM	Traditional Chinese Medicine
TEA	Triethylamine
TG	Triglycerides
THF	Tetrahydrofuran
t.i.d	ter in die
TLC	Thin Layer Chromatography
UE	Ultrasonic Extraction
US	United States
UV	Ultraviolet
WHO	World Health Organization
WHR	Waist-Hip Ratio